文献速递前列腺癌泌尿系感染

COVID-19与前列腺癌之间的交互作用

Crosstalk between COVID-19 and prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-07-24

本文探讨SARS-CoV-2与前列腺癌(PCa)之间可能的交互作用。前列腺癌中使用的雄激素剥夺治疗(ADT)显示出对COVID-19的保护作用,其机制可能涉及SARS-CoV-2宿主上皮细胞靶点与PCa遗传变异及分子特征(包括AR和TMPRSS2)之间的关联。PCa治疗能否作为COVID-19患者的潜在治疗选择尚待明确。

要点

  • ADT在前列腺癌患者中可能对COVID-19具有保护作用
  • SARS-CoV-2靶点与PCa分子特征(AR、TMPRSS2)存在潜在关联
  • PCa治疗能否用于COVID-19患者仍需进一步研究

核心结论

  • 前列腺癌与COVID-19之间可能存在隐藏联系,ADT显示出对COVID-19的保护作用。

主要发现

  • ADT在前列腺癌患者中显示出对COVID-19的保护作用。
  • SARS-CoV-2宿主上皮细胞靶点与PCa遗传变异和分子特征(包括AR和TMPRSS2)之间存在潜在关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A new coronavirus, named SARS-CoV-2, emerged in Wuhan city, China, in December 2019 causing atypical pneumonia and affecting multiple body organs. The rapidly increasing numbers of infected patients and deaths due to COVID-19 disease necessitated declaring it as a global pandemic. Efforts were combined since then to rapidly develop a treatment and/or a vaccine to combat the deadly virus. Drug repurposing approach has been pursued as a temporary management tactic to treat COVID-19 patients. However, reports about the efficacy of many of the used drugs had been controversial with a dire need to keep the ongoing efforts for rapid development of new treatments. Promising data came out pointing to a possible hidden liaison between prostate cancer (PCa) and COVID-19, where androgen-deprivation therapies (ADT) used in PCa had been shown to instigate a protective role against COVID-19. Delving into the possible mechanisms underlying the crosstalk between COVID-19 and PCa alludes a potential association between SARS-CoV-2 targets on host epithelial cells and PCa genetic aberrations and molecular signatures, including AR and TMPRSS2. The question remains: Can PCa treatments serve as potential therapeutic options for COVID-19 patients?

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bahmad HF, Abou-Kheir W. Crosstalk between COVID-19 and prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32709978. doi:10.1038/s41391-020-0262-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。